Treatment of typhoid fever
Reading File
Finding Sources
Searching PubMed
"typhoid fever"[MeSH Terms] AND treatment
Finding Sources
Reading Article
Reading File
Reading File
Finding Sources
Searching the Web
typhoid fever treatment guidelines 2024 WHO antibiotics fluoroquinolone resistant
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have excellent comprehensive data. Let me compile the complete answer.
Treatment of Typhoid (Enteric) Fever
Typhoid fever is caused by Salmonella Typhi (and paratyphoid by S. Paratyphi A, B, C). Untreated, mortality is 10–30%; appropriate antibiotic therapy reduces this to <1%. Treatment choice is governed primarily by susceptibility patterns of locally or travel-acquired strains.
Antibiotic Susceptibility Patterns — Why They Drive Treatment
| Pattern | Resistance Profile | Epidemiology |
|---|---|---|
| Fully susceptible | Susceptible to all first-line agents | Declining globally |
| Multidrug-resistant (MDR) | Resistant to chloramphenicol, ampicillin, TMP-SMX | Indian subcontinent, Southeast Asia, Africa |
| Fluoroquinolone-resistant / DSC | MIC ≥0.125 µg/mL (decreased susceptibility to ciprofloxacin) | Indian subcontinent, Africa; associated with clone H58 |
| Extensively drug-resistant (XDR) | MDR + resistant to fluoroquinolones AND ceftriaxone | Pakistan (ongoing outbreak since 2016); susceptible only to azithromycin and carbapenems |
⚠️ Most typhoid fever diagnosed in the United States in returning travelers is fluoroquinolone-nonsusceptible — fluoroquinolones should NOT be used empirically without susceptibility data, especially in travelers from South Asia.
Antibiotic Therapy for Enteric Fever in Adults
(Harrison's Table 171-1)
| Indication | Agent | Dose (Route) | Duration |
|---|---|---|---|
| Empirical | Ceftriaxone^a | 2 g/day IV | 10–14 days |
| Ciprofloxacin^b | 500 mg bid PO or 400 mg q12h IV | 5–7 days | |
| Azithromycin^c | 1 g/day PO | 10 days | |
| Fully susceptible — optimal | Ceftriaxone | 2 g/day IV | 10–14 days |
| Ciprofloxacin | 500 mg bid PO or 400 mg q12h IV | 5–7 days | |
| Fully susceptible — alternative | Azithromycin | 1 g/day PO | 5 days |
| Amoxicillin | 1 g tid PO or 2 g q6h IV | 14 days | |
| Chloramphenicol | 25 mg/kg tid PO or IV | 14–21 days | |
| TMP-SMX | 160/800 mg bid PO | 7–14 days | |
| MDR (no ceftriaxone resistance) | Ceftriaxone | 2 g/day IV | 10–14 days |
| Ciprofloxacin | 500 mg bid PO | 5–7 days | |
| Azithromycin | 1 g/day PO | 5 days | |
| XDR / Ceftriaxone-resistant | Meropenem | 1 g q8h IV | 10–14 days |
| Azithromycin | 1 g/day PO | 10 days |
^a Preferred empirical agent for uncomplicated disease and for travelers from high-resistance areas
^b Use only if susceptibility confirmed; not recommended empirically in South Asia travelers
^c Preferred for uncomplicated disease where oral therapy is appropriate; lower relapse rate than fluoroquinolones
Specific Clinical Scenarios
Uncomplicated Typhoid Fever
- Oral azithromycin (1 g/day × 5–10 days) is highly effective and associated with lower relapse rates than fluoroquinolones or ceftriaxone (2024 systematic review of 14 RCTs, PMID: 39623850)
- Oral cefixime is an alternative but carries higher risk of clinical failure and longer time to defervescence vs. fluoroquinolones
Severe / Complicated Typhoid Fever
- IV ceftriaxone 2 g/day or IV meropenem (for XDR strains)
- Corticosteroids (dexamethasone IV 3 mg/kg initial dose, then 1 mg/kg q6h × 48h total) are indicated in critically ill patients with delirium, obtundation, stupor, coma, or shock — reserved for life-threatening toxemia; beneficial especially in children with severe disease
Children
- Same principles apply; fluoroquinolones are generally avoided unless confirmed susceptible
- For MDR/XDR: ceftriaxone or azithromycin; carbapenems for XDR when azithromycin cannot be used
Chronic Carrier State Treatment
Up to 1–4% of patients with S. Typhi infection become chronic carriers (organism shed in stool >1 year, typically residing in gallbladder).
- Ciprofloxacin or norfloxacin PO × 4 weeks (high biliary concentration) — first-line
- Ampicillin high-dose IV if fluoroquinolone not tolerated and strain is susceptible
- Cholecystectomy followed by antibiotics may be necessary if medical therapy fails (especially with cholelithiasis)
Management of Complications
| Complication | Management |
|---|---|
| Intestinal perforation | Emergency surgery (resection or primary closure) + broad-spectrum antibiotics covering enteric organisms; mortality 10–30% |
| Intestinal hemorrhage | Transfusion, bowel rest; surgery if uncontrolled |
| Hemophagocytic lymphohistiocytosis (HLH) | Rare but serious; treat typhoid + consider HLH-directed therapy |
| Hepatitis / hepatic dysfunction | Supportive; avoid hepatotoxic agents |
Supportive Care
- Antipyretics (paracetamol preferred)
- Adequate hydration and nutrition
- Careful fluid balance in patients with abdominal distension (risk of perforation)
- Monitor for complications especially in weeks 2–3 of illness
Key Points on Resistance (2026 Context)
- XDR typhoid from Pakistan: suspect in any traveler returning from Pakistan/India with typhoid; treat with meropenem or azithromycin
- A 2026 systematic review (PMID: 41990105) documented increasing antimicrobial resistance burden in S. Typhi in India from 1977–2024
- Fluoroquinolone-nonsusceptibility is now the dominant phenotype in South Asia travel-acquired cases — do not use fluoroquinolones empirically
Vaccination (Prevention)
Two vaccines are available:
- Injectable Vi polysaccharide (Typhim Vi): single dose, 60–80% efficacy, ≥2 years of age
- Oral Ty21a (Vivotif): 4 oral doses on alternate days, ≥6 years of age
- Typhoid conjugate vaccine (TCV): WHO-recommended for endemic countries; superior immunogenicity especially in children <2 years; a 2025 meta-analysis confirmed real-world effectiveness (PMID: 41125003)
This is a shared conversation. Sign in to Orris to start your own chat.